Promising results in unresectable HCC with dual blockade of PDL-1 and VEGF

Atezolizumab in combination with bevacizumab is a promising first-line treatment option for people with unresectable hepatocellular carcinoma, delegates at the European Society for Medical Oncology 2019 meeting in Barcleona have heard. Presenting the results of the Phase 1b GO30140 study as a late breaking abstract Dr Michael Lee, MD, of the University of North Carolina ...

Already a member?

Login to keep reading.

© 2021 the limbic